Αρχική World News High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in... World News High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma Από Ogkologos - 20 Αυγούστου, 2026 157 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATRix/IELSG43 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... 30 Ιουνίου, 2023 Research with Integrity – the madness of short methods 7 Δεκεμβρίου, 2022 Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who... 28 Νοεμβρίου, 2023 Temporary Interruption of Endocrine Therapy for Pregnancy, Including Use of Fertility... 20 Ιουλίου, 2026 Φόρτωση περισσοτέρων HOT NEWS ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... Darolutamide Delays the Spread of Some Prostate Cancers England moves to a single-dose HPV vaccine From smart knives to virtual reality tumours: five innovations in understanding...